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REGULATION OF PRESCRIPTION DRUG
ADVERTISING: MEDICAL PROGRESS AND
PRIVATE ENTERPRISE
RicHARD B. RUGE*
Communication of new developments in medicine to practicing physicians is an
essential step in implementing scientific progress. Each year the pharmaceutical
industry spends an estimated $75o million in promoting drug products.1 As a result
of this barrage of advertising, amounting to $3ooo for every doctor in the United
States, a new drug may be widely prescribed within weeks after it has been placed
on the market. Recently, the Food and Drug Administration (FDA) has in-
creasingly questioned whether the advertising techniques of drug firms contribute to
sound medical progress by helping doctors make informed choices among competing
products or instead succeed in selling drugs by misleading claims, omission of crucial
data, and inappropriate emotional appeals.
This article examines recent confficts between the FDA and the drug industry
over the purpose of prescription drug "advertising," as that term is peculiarly defined
under the Food and Drug Act.2 To the FDA, advertisements in medical journals
should constitute "post-graduate education" through which doctors learn both the
advantages and drawbacks of new drugs. To industry, advertisements function
only to provoke doctors into investigating new drugs through detailed information
available in other manufacturer-supplied literature ("labeling") or from independent
sources.4 The FDA has warned industry to comply with its regulations or find itself
altered "significantly, . . . beyond your present fears, and ...beyond recall."'
Replying that the FDA exploits the consumer "as a device, or a pretext, for adding
further to government power at the expense of the strength and independence of
private enterprise,"' the pharmaceutical industry in 1963 brought the first law suit
challenging FDA rules since passage of the basic act in i938.
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BACKGROUND OF THE KEFAUVER AMENDMENTS
Prior to the enactment in 1962 of the so-called Kefauver amendments8 to the
1938 act, the jurisdiction of the Food and Drug Administration reached prescription
drug "labeling" but not its "advertising." The statute both before and after the
amendments defined labeling to include all "labels," plus other written material on a
drug's immediate container or "accompanying such article."' Before T962, the FDA
gave labeling a broad construction (by expanding the term accompanying) to bring
much of the informational type of drug promotion under its control. Thus the
agency regulated direct mail advertising to doctors as well as material left in the
office by detail men, drug industry salesmen. At the same time, the definition of
advertising contracted to cover only newspaper and journal advertisements. This
segment of drug promotion fell under the jurisdiction of the Federal Trade Com-
mission (FTC).10
However narrow its definition, advertising was extensive in quantity and played
an important role in selling drugs. In 1958, for example, the drug industry paid
for 3,790,908,000 pages of advertising in medical journals. The American Medical
Association (AMA), the largest publisher of prescription drug ads in the world,
grossed $io.i million in 1963 from ads in its twelve scientific journals and its laymen's
monthly. This large volume of material plus the insistent intrusion of detail men
have prompted doctors' complaints about the burden imposed on their time."1
Despite these facts, the FTC prior to 1962 possessed little power over drug ads.
Advertisements directed solely at physicians-so long as they listed quantitative
ingredient information and contained no false representation of a material fact-
were specifically excluded from FTC control, on the theory that doctors have an
expertise enabling them to evaluate drug claims. This rationale probably made
sense prior to the prescription drug "revolution" which occurred at the end of the
Second World War. Until then the number of drugs available had been relatively
limited, and a doctor could fend for himself in selecting medicines; he needed little
protection from the law or from regulatory agencies.
But today some eighty new drugs are cleared each year by the FDA;' 2 and ninety
per cent of all prescriptions call for drugs manufactured within the past fifteen
years. 13 One economist attributes this extensive introduction of new drugs--or at
8 Pub. L. No. 87-781, 76 Stat. 780 (1962).
°21 U.S.C. §321(m), (k) (1964).
"Federal Trade Commission Act, 15 U.S.C. §§ 52-57 (1964).
"1 See N.Y. Times, June 13, 1966, at 26, col. .
"
2Hearings on Competitive Problems in the Drug Industry Before the Monopoly Subcomm. of the
Senate Select Comm. on Small Business, 9oth Cong., Ist Sess. 4 (x967) (statement by James L. Goddard,
Commissioner of Food and Drugs).
"
1 Hearings on Drug Safety Before the Subcomm. on Intergovernmental Relations of the House Comm.
on Governmental Operations, 88th Cong., 2d Sess. 14 (1964) (statement by George P. Larrick, Com-
missioner of Food and Drugs).
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least of new combinations and dosage forms of old drugs-to industry's efforts to
replace price competition among relatively standardized drugs with product differ-
entiation or competition "in innovation."' 4  As a part of these efforts, companies
make heavy advertising outlays to maintain their existing market share through
constant introduction of "new" drugs. A new product will reach its peak in the
second year following its introduction, then decline "rapidly in relative importance."' 5
More important, today advertising not only sells new drugs but also tells the
physician about their existence and their claimed effectiveness for the first time. An
AMA study,"G for example, disclosed that medical journal ads constitute one of the
largest sources of information to practitioners about newly discovered drugs. Forced
to "contend with subtle overpowering promotion and the complexities of modern
medicine," today's doctor cannot effectively fend for himself, "especially if he is to
be 'educated' by the very purveyors of products which require his prescriptions."'
Prior to 1962 responsible doctors began to question the propriety of educating
physicians through unpoliced ads. Pointing out that many doctors assume that
at least some reputable firms consistently disseminate reliable information, Dr. Charles
D. May wrote:"
The traditional independence of physicians and the welfare of the public are
being threatened by the new vogue among drug manufacturers to promote their
products by assuming an aggressive role in the "education" of doctors.... Is the
public likely to benefit if practicing physicians and medical educators must per-
form their duties amidst the clamor and striving of merchants seeking to increase
the sales of drugs by conscripting "education" in the service of promotion? Is
it prudent for physicians to become greatly dependent upon pharmaceutical
manufacturers for support of scientific journals and medical societies, for enter-
tainment, and now also for a large part of their education?
Another distinguished doctor has more recently charged that "persuasive propa-
ganda of advertising literature and of visiting detail men" causes physicians to shift
"repeatedly and needlessly from one drug to another."'9
[Doctors] are being systematically brainwashed by expensive advertising in the
pages of medical journals, by the daily influx of mountains of advertising mail,
by free throw-away "educational" pamphets published by commercial agencies for
the promotion of drug sales, and by visiting detail men, who go from door to
1 Comanor, Research and Competitive Product Differentiation in the Pharmaceutical Industry in the
United States, 31 EcONOMI A 372-73, 375 (z964). See Steele, Monopoly and Competition in the Ethical
Drugs Market, 5 J. LAw & EcoN. 131, 141 (x962). See generally J. BACKMAN, ADVERTiSING AND CoM-
PETrriON (z967).
15 Comanor, supra note 14, at 376.
"Attitudes of U.S. Physicians Toward the American Pharmaceutical Industry, Study conducted by
Ben Gaffin and Associates, Inc., Chicago, Ill., in 1959 for the AMA, cited in S. REP. No. 448, at i9o.
See also Demeritt, Effectiveness of Pharmaceutical Promotion to Hospital Pharmacists, 23 AM. J. HosW.
PHARMACY 13, 16-17 (1966).
'
7 May, supra note I, at 8-9.
-id. at z.
l' Baehr, Drug Costs and the Consumer, in DRuGs IN OUR SOCIETY 179, 182 (P. Talalay ed. 1964).
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door of physicians' offices leaving elaborate samples of new drugs and valueless
combinations of old drugs, together with reams of impressive but biased literature.
It is utterly impossible for most busy physicians to separate the wheat from the
chaff in this enormous volume of information and misinformation."0
Hearings held by Senator Estes Kefauver before the Senate Subcommittee on Anti-
trust and Monopoly in 1961 and 1962 focused attention on such abuses. Out of these
hearings, with the help of public concern aroused by the thalidomide tragedy, there
developed the Drug Amendments of 1962.
The amended law placed on the pharmaceutical industry a greater responsibility
to present factual and undistorted information to doctors than did the 1938 act, and
gave jurisdiction to regulate prescription drug advertising to the Food and Drug
Administration,2 ' leaving control over nonprescription drug advertising to the FTC.
Although FDA regulations issued under the 1962 amendments have imposed similar
requirements for both advertising and labeling, the distinction between the two kinds
of printed literature remains important-for example, side effects must be fully stated
in labeling but may be summarized in advertising 2
The amended statute does not specifically give the FDA authority over oral
promotional statements made by detail men. These salesmen are also an important
source of information about new drugs, making an estimated i 8 to 20 million calls
a year on doctors and druggists.2 3  The original version of the 1962 amendments in-
cluded oral claims as advertising; this provision,2 4 not enacted, would have required
detailers to supply the generic name and warnings for drugs. Absent such a rule,
promotional statements by detailers cannot be easily categorized as either labeling
or advertising. The FDA does, however, have jurisdiction over literature left by
detailers with doctors. The judiciary may fill this legislative gap. A recent case
held a manufacturer liable where the company had warned doctors of a newly dis-
covered side effect by product cards and letters but its detailers had remained
silent.25
President Johnson has proposed legislation to control the unsolicited distribution
of samples, 26 another major form of drug promotion costing $ioo million per year.
The proposed Drug Safety Act of 1967 would not restrict person-to-person distribu-
tion from detailer to physician but would forbid drug companies to send samples
through the mails except to a doctor requesting samples of a particular drug in
writing.
Regulations covering prescription drug advertising can be divided into three
" Id. at 181-82.
2121 U.S.C. § 352(n) (1964).
"2Compare 21 C.F.R. §§ i1o6(b) (3) (i), (4 )(i) (1967) with 21 C.F.R. § 1.05(e) (1967).
22 R. HMUms, THE R ,L VOICE 89 (1964).
"S. 1552, 87th Cong., Ist Sess. § 4(A)( 7 ) (i96i).2 Yarrow v. Sterling Drug, Inc., 263 F. Supp. 159 (D. S.D. 1967).
2 H.R. 3913, 9oth Cong., ist Sess. (1967).
17 Medical Tribune, April 4, r966, at i, col. 2.
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general areas. First, the FDA has issued controversial rules controlling drug names;
related to these requirements are FDA rules compelling disclosure of certain essential
ingredient information. Second, additional information needed before prescribing a
drug-its side effects and contraindications-must also be listed. Finally, the FDA
has recently moved to regulate the content of drug advertisements to ensure that
the limits of the drug's effectiveness are accurately portrayed. These subjects are
taken up below.
II
REGULATION OF DRUG NAMES
A discrete drug substance may be known by three types of names. Its chemical
name simply lists every part of a drug's molecular structure. Its generic name
abbreviates the components but still informs a doctor of the drug's chemical com-
position, from which he can determine its general effect on the body. Ordinarily
a drug will have only one generic or nonproprietary name. Finally, a drug is sold
under a trade or brand name which identifies the drug with a particular manufac-
turer but conveys little information about its nature or composition. Several manu-
facturers often market the same chemical substance under different trade names.
Senator Kefauver felt that the purpose of the vast sums spent by the drug in-
dustry on promotion was to persuade doctors to prescribe by trade name rather than
by generic name.28 Since the same product sold by trade name may cost several times
as much as when sold by generic name,2 advertising which planted the brand name
firmly in the prescribing doctor's mind left the ultimate consumers "captives of the
drug industry." 0 This promotional effort largely succeeded; 91.9 per cent of 1964
prescriptions called for trade name drugs.3
Although Congress rejected Senator Kefauver's chief proposal for encouraging pre-
scription by generic name (government licensing of drug manufacturers), 82 the
1962 amendments require that a drug's "established name" must appear on each
piece of promotional material in "direct" conjunction with its trade name. 3 To alert
doctors to the exact relationship between the two designations, the established name
must be surrounded by brackets or preceded by a phrase such as "brand of." The
established name must be "printed prominently and in type at least half as large as
21 S. RFP. No. 448, at io5, 231-44; 107 CONG. REG. 5638 (196i) (remarks of Senator Kefauver).
29 S. REP. No. 448, at 105, 231-44. See generally R. BuRtex, THE HAaNBooK op' PaciRePToN DauGs
(3967). However, a survey conducted for the AMA of ioo Chicago drug retailers concluded that generic
name prescribing did not necessarily cut drug costs. N.Y. Times, June 9, 1967, at 26, col. 3.
so 107 CoNG. REc. 5638 (196I) (remarks of Senator Kefauver).
8"N.Y. Tunes, June 13, 1966, at 27, col. i. Additional factors may explain this fact. The generic
name is often omitted in drug advertising and labeling; the trade name may be easier to pronounce, spell,
and therefore remember; and it has been suggested by industry detail men that drugs produced and sold
by smaller companies are of substandard quality. S. REP. No. 448, at 232-34.
32S. 1552, 87th Cong., ist Sess. §§ 4(A)(7), (13) (x6x).
3 21 U.S.C. §§ 352(e), (n) (1964).
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that used for any trade or brand name."3  In addition, the amendments seek to
assure doctors of drug quality by certain safeguards over manufacturing, including
registration and inspection.35
Early in 1963 the Food and Drug Administration issued regulations requiring
that the established name of a prescription medicine accompany every appearance
of the drug's trade name on all labels, labeling, and advertising, no matter how many
times the brand name may be repeated on any single page.3 6 The FDA contended
that the "every-time" regulations were crucial to the 1962 amendment in light of
the "evident intent" of Congress to popularize established names.3 7 Arguing that
the statute dictates only the manner in which the generic name must appear, and not
its frequency, the Pharmaceutical Manufacturers Asssociation and thirty-seven of its
members sought a declaratory judgment in the U.S. District Court for Delaware,
invalidating the regulations as exceeding the FDA's statutory authority 8
This suit in 19633" was the first legal challenge to FDA regulations since passage
of the basic act in x938. The drug industry's concern extended beyond the estimated
million-dollar cost of reprinting its existing labels to comply with the every-time
requirement." The regulations struck at the purpose of drug promotion, the im-
plantation of trade names in the doctor's mind; they sought to lower drug prices
by educating physicians to prescribe by generic names. But increased familiarity
with nonproprietary names, the industry feared, would endanger its investment in
brand names and in research for new and better products, little of which is under-
taken by smaller, generic-name producers.
It was claimed that conspicuous disclosure of the generic name, to which the
industry did not object, would notify the physician of the drug's active ingredients.
He could then choose among the various sources producing the same or comparable
chemical substances at different prices. Constant repetition of the established name,
on the other hand, might make advertising and labeling less readable. (In fact,
compliance with the every-time rule does not substantially affect over-all appear-
ance.41) Finally, the industry complained that the regulations would induce doctors
to believe that drugs "with the same established name are always and in all respects
s 21 C.F.R. § .104(g), i.io5(b) (x967). The regulations prescribe that "[T]he established name
shall have a prominence commensurate with the prominence with which such proprietary name or
designation appears, taking into account all pertinent factors, including typography, layout, contrast, and
other printing features." 21 C.F.R. § I.105(b)(2) (1967).
a;21 U.S.C. § 331(p), 35I(a), 352(0), 374 (1964); § 360 (1964, Supp. II, 1965-66).
21 C.F.R. § 1.o4(g)(1), I.105(b)(I) (x967).
57 F.D. Cosat. L. REP., para. 40,060 (1963).
" Complaint, Abbott Laboratories v. Celebrezze, Civil No. 2737 (D. Del. 1963), reported in F.D.
Cosm. L. REP., para. 40,060 (1963).
" Abbott Laboratories v. Celebrezze, 228 F. Supp. 855 (D. Del. 1964), reu'd, 352 F.2d 286 (3d Cir.
1965), rev'd and remanded sub nom., Abbott Laboratories v. Gardner, 387 U.S. 136 (1967).
"o N.Y. Times, Sept. 6, x963, at 1, col. 5.
"1 See, e.g., Advertisement for Polycillin (ampicillin trihydrate), f.A.M.A. July 31, 1967, at x-3.
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identical," when in fact drugs with the same generic name but different proprietary
names "can and do differ in their therapeutic effect."4
The district court invalidated the regulations as contrary to the intent of the 1962
amendments.43  The Third Circuit reversed on procedural grounds, holding that
there was no actual case or controversy as required for justiciability under the Declara-
tory Judgment Act44 because no real threat of immediate prosecution had been
presented 5 On May 22, 1967, the Supreme Court reversed this decision, finding
that "the impact of the regulations ... is sufficiently direct and immediate so as to
render the issue appropriate for judicial review at this stage," ' and remanded the
case to the court of appeals for decision on the substantive issues.
On October 2o, 1967, the day set for further argument in the Third Circuit, the
FDA and PMA announced settlement of the litigation.4 7  The FDA will replace
the contested every-time rules with new regulations. On any page of advertising or
labeling which "features" a drug's trade name, the generic name must appear "in
direct conjunction with" and in type one-half as large as the brand name each time
the latter is featured, but need not appear again in promotional copy on the same
page. If a trade name is used but not "featured," the generic name must appear at
least once with the most prominent display of the trade name. In addition, each
column of text providing detailed information on effectiveness or side effects must
include the generic name at least once "in association with" the trade name, if used,
in the same size type as that used for the text. If the trade name appears in type
size larger than that used for the column text, the generic name must again be half
as large as the trade name.
In light of publicity recently given to generic-name prescribing in recent con-
gressional hearings,48 however, the FDA need not insist vigorously on "educating"
doctors to use generic name drugs, so long as the generic name is "prominently"
disclosed in drug advertising. A survey of ads in recent journals shows that, con-
trary to FDA regulations, the generic name type face does not always appear half as
bold or wide as that used for the trade name; in many cases, the generic name is not
preceded by a phrase such as "brand of" nor surrounded by brackets or parentheses.
12 For the industry's position, see the complaint and plaintiff's briefs filed in 228 F. Supp. 855. Re-
cently, the FDA ordered generic manufacturers to stop marketing their versions of the antibiotic
chloramphenicol, sold as Chloromycetin by Parke, Davis, & Co. Parke-Davis had submitted test data
to the FDA indicating that its version entered the blood stream quicker than the others. Some medical
experts attribute this advantage to the different shapes of chloramphenicol crystals used in the trade-name
drug. Wall Street Journal, Jan. 22, 1968, at 6, col. 2; id., Dec. 26, x967, at 4, col. 3. The FDA has not,
however, announced any rule requiring generic manufacturers to show that their products work as cffec-
tively in patients as the chemically equivalent brand-name products.
43228 F. Supp. at 864.
"428 U.S.C. § 2201 (1964).
a 352 F.2d at 29x.
146 387 U.S. at 152.
"'See Food and Drug Reg., 21 C.F.R. § .o105, 33 Fed. Reg. 3217-18 (Feb. 21, 1968).
4 Hearings on Competitive Problems in the Drug Industry Before the Monopoly Subcomm. of the
Senate Select Comm. on Small Business, goth Cong., ist Sess. (1967).
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The new rules, of course, may lead to new controversies over their exact interpreta-
tion, but they appear to be a reasonable compromise. Commentators have split on
the question whether the now-withdrawn every-time regulations were consonant with
congressional purpose.49 Ambiguity in the statutory provision on generic names
and in its legislative history probably indicate that Congress had no "intent" on the
question of frequency. The AMA, which generally supports the industry against
the FDA, urges doctors to prescribe by trade name. 0
III
DIscLoSuRE OF SIDE EFFECTS
More than one million adverse reactions to drugs occur annually in the United
States. These unwanted effects often occur even when a drug is administered accord-
ing to the manufacturer's directions. Information on a drug's recurrent side effects,
or rarer but serious adverse reactions, is obviously important to a doctor weighing
alternative medications, especially since many side effects are not allergic or unusual
genetic reactions peculiar to the patient but pharmacological effects of the drugs51
Similarly, the doctor must know what pathological conditions contraindicate use
of the drug. The Kefauver hearings found, however, that drug manufacturers
sometimes failed to disclose to doctors or to the FDA reports in their possession of
serious and even fatal side effects.52
In particular, the hearing revealed that prescription drug advertisements failed
to list or discuss possible adverse reactions. A survey of promotion in six leading
medical journalsP covering thirty-four important trade name drugs advertised in
a total of 2o33 pages during a nine-month period ending in March i959, found
that in eighty-nine per cent of the ads there was "no reference to side effects at all or
only a short dismissal phrase which was typically less a warning than a reason
for prescribing." Among the advertisements surveyed were several for Diabinese
(chlorpropamide), an oral antidiabetic introduced in 1958 by Chas. Pfizer & Co., Inc.
Although its promotion claimed an "almost complete absence of unfavorable side
effects," a report prepared for Pfizer showed twenty-seven per cent incidence of side
effects, including jaundice.5" Doctors polled by an AMA study on misleading
advertising termed such failure to cite side effects "the most heinous crime a pharma-
ceutical company can commit."' 5
11 Compare Note, Drug Amendments of z962-Generic Name Prescribing: Drug Price Panacea?, 16
STAN. L. REv. 649 (1964) with Note, The Drug Amendments of z962: How Much Regulation?, 18
RUTGERS L. REV. IO, 127-30 (1963) and Sweeney, The "Generic Every Time" Case: Prescription Drug
Industry in Extremis, 21 FOOD DRUG Cosm. L.J. 226 (z966).
'o Editorial, Drug Names, 19o J.A.M.A. 542 (1964).
N.Y. Times, May 5, 1965, at 63, col. x (study at Johns Hopkins University).
1 2 M. MiNTz, THE TnERAPTIc NIGH-riARE X3-32 (965).
S. REP. No. 448, at I99. The journals surveyed included JAMA, the New England Journal of
Medicine, and Medical Economics.
"Id. at 211, 218.
" See 2o8 CONG. Rac. 22,o86 (2962) (remarks of Representative Dingell).
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Drug industry spokesmen counter that physicians can obtain full side-effect in-
formation elsewhere, particularly on the package insert which must accompany each
prescription drug and sample and on all promotional labeling."  They contend
that advertisements, aimed solely at doctors, serve only as "product reminders" and
thus should not be treated as labeling. However, this argument begs the question
of the importance of journal advertising in presenting drug news and overstates the
adequacy of alternative sources of information on side effects. First, doctors often
ignore the vast quantities of promotional labeling sent to their offices; they are most
apt to study ads appearing next to scientific articles in prestigious medical publica-
tions such as the Journal of the American Medical Association (JAMA) and the
New England Journal of Medicine."  Second, the package insert goes not to the
doctor who needs the "full disclosure" labeling but to pharmacists.
The better journals do carry reports critical of new drugs. In early 196o, for
example, JAMA noted thirty-five cases of baby girls with male characteristics born
to women who had been given Norlutin (norethindrone), a hormone used in
gynecologic disorders, during pregnancy."8 But ads for Norlutin in JAMA during
the following three months did not cite this side effect. Despite the fact that warn-
ings given only in journal articles (which generally would appear but once) may be
ineffective to deter improper use of a drug, JAMA did not request the advertiser
to add a warning.59
Moreover, the responsible medical publications may not review all the new
drug products unleashed yearly. Another potential source of information, Physicians'
Desk Reference, a commercially produced manual of therapeutic agents distributed
free to doctors, carries warnings supplied by manufacturers. The FDA has filed
criminal informations against two drug compaines for allegedly failing to make full
side-effect disclosures in PDR, which the agency considers labeling; Pfizer Labora-
tories recently notified doctors that the FDA considered its I967 PDR entries for two
drugs inadequate."0 The sharpest critic of new drugs is the Medical Letter, which
carries no advertising. Its effectiveness is limited, however, because fewer than 35,000
doctors subscribe.
To meet this need for disclosure, the 1962 amendments require any prescription
drug advertisement listing indications or dosage recommendations-that is, any ad
except a strictly reminder piece-to contain "a true statement of ... information in
brief summary relating to side effects, contraindications, and effectiveness" as called
for by regulations. 1 In what detail must relevant side effects and contraindications
" N.Y. Tmes, July 20, 1963, at ig, col. i (criticism of FDA by PMA).
" S. REP. No. 448, at 16o-64.
" Wilkins, Masculinization of Female Fetus Due to Use of Orally Given Progestins, 172 J.A.M.A.
1028 (ig6o).
"M. MINTz, supra note 52, at 84.
'o Washington Post, May 24, z967, at 2, col. x.
6121 U.S.C. § 352(n) (1964); 21 C.F.R. § I.1O5(e) (1967).
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be presented? The answer depends on the size of the advertisement and the
quantity of side effects. An ad of three pages or less, condensing information on effec-
tiveness, may "concisely" present each side effect found in the drug's full-disclosure
labeling; in an ad of more than three pages presenting extensive claims of effective-
ness, the side effect information should similarly expand into a "discussion" of pre-
cautions. 2 But there is not precise matching requirement for stating the two
types of information in an equal number of words, an equal amount of space, or in
the same type size. Thus, if headlines, advertising leads, and photographs are used
to convey information on effectiveness, similar techniques need not be used to com-
municate side effect information.
While the FDA may consider the size of the ad and the conditions for which the
drug is offered in determining whether there has been adequate disclosure, the
statute only requires a "brief summary," which Senator Kefauver described as a "fair
condensation of the full disclosure information already required in labeling.... 3
To comply with the advertising regulations, the manufacturer ordinarily summarizes
the precaution and side-effect section of the package insert. For example, compare
the 1966 package insert warning as to renal impairment and the corresponding
advertising side-effect information for Declomycin (demethylchlortetracycline HCO):
Labeling Advertising6 5
If renal impairment exists, even usual Reduce dosage in impaired renal function.
oral or parenteral doses may lead to exces-
sive systemic accumulation of the drug and
possible liver toxicity. Under such condi-
tions, lower than usual doses are indicated
and if therapy is prolonged, . . . serum level
determinations may be advisable.
To test compliance with its disclosure regulations, the FDA must gather and
evaluate reports on adverse reactions, especially those occurring after a new drug is
first sold. Until recently, there were no reliable systems for retrieving such informa-
tion; for example, most hospitals did not encourage members to record recognized
drug reactions. Today, side-effect data from numerous sources feeds into the
FDA's Information Center on Adverse Reactions and Hazards, where it is studied
and catalogued. Some 66oo hospitals supply the FDA with drug information.
The agency also collaborates with the AMA central registry of adverse reactions,
which receives drug news from hospitals not reporting to the FDA and from
doctors in private practice. All federal medical services and agencies send side-effect
"
2Food and Drug Reg. § Io105(e)(5)(xxix), 32 Fed. Reg. 7535 (May 23, 1967). See letters from
George P. Larrick, former FDA Commissioner, to Gerhard A. Gesell, Oct. x, 1963, Oct. 9, 1963, reported
in F.D. Cosm. L. REP., para. 40,063 (1963).
as 1o8 CONG. REc. 22,039-40 (remarks of Senator Kefauver).
"Labeling for Declomycin (demethylchlortetracycline), dated February 1965.
" Advertisement for Declomycin (demethylchlortetracycline), J.A.M.A., Feb. 7, x966, at 48.
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reports to the FDA, and eight countries will exchange information through an inter-
national center created by the World Health Organization to provide a worldwide
early warning system for drug news."
Under the 1962 amendments the FDA requires manufacturers to record side
effects and other clinical data as received and to report information relating to the
drug's safety and effectiveness 7 The reporting regulations are important because
the manufacturer has more knowledge about the marketing experience of his drug
than any other source, since he picks up information from doctors and his detail
men.6 s The regulations have already brought to the FDA reports of adverse reac-
tions which would not have been previously available. These are screened by the
Information Center on Adverse Reactions and Hazards, which receives i5o,ooo reports
annually and may get significant information on reactions to a new drug within three
months after it is first sold. The Center may then recommend precautionary labeling,
changes in existing labeling, issuance of a warning letter, or withdrawal of the
drug from use.
In turn, the FDA publishes monthly reports on adverse reactions and a weekly
journal of literature abstracts, which are sent to cooperating hospitals and other
groups. FDA Commissioner James L. Goddard has proposed that a compendium of
drug information approved by the FDA be distributed free to doctors; if this were
done, the agency would drop its requirements that full-disclosure package inserts
accompany the marketed or dispensing package of all prescription drugs.6"
In December 1965, the Food and Drug Administration initiated its first prosecu-
tion under the advertising provisions of the 1962 amendments. 70 The FDA charged
that ads for Pree MT, marketed by Wallace Laboratories, a division of Carter-
Wallace, Inc. (formerly Carter Products), omitted essential side effect and contra-
indication information. The United States District Court for New Jersey imposed
the maximum $2,ooo fine after the defendant pleaded no contest.
Pree MT combines meprobamate, a tranquilizer sold separately as Equanil
or Miltown, with hydrochlorothiazide, which removes excess fluids from body tissues.
An ad appearing in four June 1964 issues of JAMA claimed, "Contraindications:
None known," and urged doctors to prescribe the drug for premenstrual tension.
The FDA insisted that the ad's brief summary omitted warnings that hydrochloro-
thiazide is contraindicated in patients who have had suppressed urine flow and
that patients given it should be watched for signs of serious and sometimes fatal
blood diseases; that Pree MT can precipitate gout, and that its use should be halted
in patients with severe kidney disease or liver disease; and that meprobamate may
cause skin rash, bronchial spasm, skin hemorrhages, and blood-vessel disturbances.
"6 52 DErP' STATE BULL. 814 (1965).
OTSee 21 U.S.C. §§ 3 55 (i), 0) (1964).
"Pisani, Drug Safety and the FDA, 21 FooD DRUG Cosia. L.J. 68, 74 (1966).
69 Washington Evening Star, Aug. 1i, 1967, at C-6, col. 5.
° Washington Post, Dec. 7, 1965, at 12, col. i; id., Jan. 18, 1966, at 4, cl. I-
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The FDA has also charged that Ciba Pharmaceutical Co. "kept secret" reports
showing that Elipten (amino-glutethimide), prescribed for control of epilepsy, caused
sexual precocity, masculinization of young females, and other "untoward effects";71
that Wyeth Laboratories and Merck & Co. delayed in reporting adverse effects on
the eyes of dogs caused by the controversial experimental drug DMSO (dimethyl
sulfoxide) ;72 and that Merck, Sharp, & Dohme failed to report immediately (as
required) "alarming" findings of breast cancer in four of six dogs given an experi-
mental birth control pill, MK-665 , combining mestranol and ethynerone.7
IV
REGULATION OF ADVERTISING CONTENT
The drug industry contends that once the FDA assures adequate disclosure of
effectiveness, side-effect, and contraindication information within the "brief sum-
mary" portion of an advertisement, the agency has no further jurisdiction to regu-
late the content of the ad or the promotional techniques used.74 The FDA asserts
that Congress intended the 1962 amendments to grant power "to deal completely,
and not partially, with the problems of false and misleading advertising which had
been called to its attention" during the Kefauver hearings.7 5 Thus, it is argued that
Congress introduced the phrase "brief summary" only to authorize "a stripped-down
statement of the drug's effectiveness, side effects, and contraindications when the
sponsor wished to limit the size of his ad"; and so the agency retains jurisdiction over
the entire advertisement. Exercising this power, the FDA has issued regulations
which utilize the "brief summary" provision as a counterbalance to overpromotion.
Hearings conducted by Senator Kefauver repeatedly aired criticism by physicians
of the promotional tactics used in drug advertising7 0 The problem of selling doctors
on new drug products each year, of which as few as thirteen may be new single
chemical entities,7  has led to "clamorous competitive claims" presented in a style
designed "to achieve uncritical acceptance of a preconceived message-to captivate
the mind."78 For example, Dr. Charles D. May of Columbia University has charged
that from 1958 to i96i drug firms launched an "exuberant" and "hectic" campaign
to increase sales of antibiotics; the "confused and misleading barrage of promotion"
presented "inadequate and irrelevant data" in a "triumphant tone." "The 'educa-
tional' effect on doctors was to confuse them and lead them to believe wonderful
"
1 Washington Post, Feb. 16, 1966, at 8, col. 3.
"'Washington Post, March 1o, x966, at i, col. 5.
"Washington Post, March ii, x966, at i, col. 3.
"' See Pharmaceutical Manufacturers Association, Comments on Proposed Prescription Drug Advertising
Regulations, 32 Fed. Reg. 7533-37 (May 23, 1967), filed with the FDA on August 29, 1967.
"Letter of Oct. I, 1963, supra note 62.
" S. REP. No. 448, at 164-90.
""N.Y. Times, June 4, 1967, § 3, at i, col. 2.
7 May, supra note I, at io.
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new drugs were available" when in fact what development there had been was
altogether minor. 9
Need for government regulation in this area exists partly because leading medical
publications have not strictly supervised the drug advertising which they publish.
From 1953 through 196o the AMA, which reaches over 200,000 subscribers through
JAMA, gradually relinquished its earlier policing powers over advertisements.80
Although the AMA today asserts that ads in JAMA "have been reviewed to comply
with the principles governing scientific advertising in AMA scientific publications," it
responded to the Pree MT prosecution by stating that censorship of advertisements
is "fundamentally a matter for manufacturers.""1
A drug advertising writer, in turn, places responsibility for misleading over-
promotion on the doctor. Pointing out that few physicians subscribe to the Medical
Letter, an independent newsletter attacked by industry "for presuming to pass on
advertising claims, the validity of supporting evidence, and the inherent merit of
drugs," the late Pierre R. Garai asked:2 "In light of this kind of response, is it any
wonder that drug advertisers should be unimpressed by the professional maturity
of the bulk of their audience or that campaigns for ethical drugs should sometimes
seek to manipulate physicians rather than communicate with them?" To avoid
becoming "a sitting duck for color spreads," the doctor should develop a healthy
skepticism concerning ads: "He must cultivate a flair for spotting the logical loophole,
the invalid clinical trial, the unreliable or meaningless testimonial, the unneeded im-
provement and the unlikely claim. Above all, he must develop greater resistance to
the lure of the fashionable and the new."' 3 The industry would presumably react
to critical appraisal of its ads by supplying more reliable information.
Aside from the dubiousness of his proposition that responsibility for providing
accurate advertising lies with the reader, Garai's argument can be criticized on two
grounds. Doctors do not have time to check claims by ferreting out more authentic
analyses elsewhere. And the evidence cited in the ads themselves as backing up
claims made may consist of unpublished data ("personal communications"), case
reports in the company's files, exhibits at meetings, testimonials from anonymous
sources, and citations from inaccessible or inferior journals.8 4
To fill this gap in control over drug ad content, the FDA issued in 1963 two
important regulations. The first required a "fair balance . . . in presenting the
information on effectiveness and that on side effects and contraindications.""5 The
second, which the FDA considered part of the "fair balance" requirement, stated
9 Id. at 3.$OR. HAmus, ThE REAL VorcE 126 (1964).
"
1 Washington Post, Dec. 7, 1965, at 12, Col. X.
"2 Garai, Advertising and Promotion of Drugs, in DRUGS IN OutR SOciETY i89, 196 (P. Talalay cd.
1964).
" Id. at x99.
"
4 May, supra note i, at ii.
821 C.F.R. § 1.105(e) (z967).
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that information concerning side effects and contraindications "shall appear in
reasonably close association with the information concerning effectiveness and shall
have the same relative degree of prominence as the information concerning effective-
ness, taking into account all pertinent factors, including typography, layout, contrast,
and other printing features. 8 6
The FDA interpreted these regulations to require at least that information on
side effects given as part of the brief summary be readable, that is, that disclosure of
precautions must be effective as well as adequate. Thus the type size used should
compare reasonably with that describing the drug's benefits and in no case be unduly
compressed s7  Headings such as "Side Effects," "Contraindications," and "Precau-
tions"--and not meaningless terms such as "In Summary" or "Special Considera-
tions"--must introduce and plainly identify the warning data.
In addition to ensuring the readability of the cautionary portion of advertise-
ments, the FDA required that ads be arranged so that "this important information
will be read." Photographs, headlines, and type size must not overwhelm "essential
side effect and contraindication information ... [or] minimize its disclosure as part
of the total message the advertisement conveys." For example, although the fair
balance regulation does not require an ad containing a picture relating to a drug's
effectiveness also to contain a picture relating to side effects, the former should not
overplay the effectiveness, nor suggest use of a drug when contraindicated, nor
create an impression that minimizes pertinent side effects. Similarly, information
on indications already presented by graphic means, headlines, or discussion in the
body of the ad should not be unnecessarily repeated in the brief summary portion so
as to divert doctors from reading the side-effect information. Visual appeal of the
summary report, as compared with the information on effectiveness, must be
sufficient to make it a "conspicuous and easily perceived part of the total advertise-
ment."
The FDA rules rest on the concept that precautionary information about drugs
"should be presented as a part of the central message of the advertisement" to give
a fair and balanced picture of the "good and the bad" of the drug!" The brief sum-
mary thus plays a more important role than that of merely supplying a list of
warnings for the conscientious doctor to read. Even if the side-effect information may
be obtained elsewhere, and even if the doctor does not scrutinize the summary, its
prominence reminds him that there are limits to the drug's effectiveness. And it
provides a measuring rod against which the more extravagant claims in the ad may
be tested.
Be 21 C.F.R. § .I05(i) (x967). These regulations have been carried forward, in modified language,
in the new FDA advertising rules.
87 Statements in this and following paragraphs based on Letters, supra note 62.
8 8 Letter of Oct. 9, x963, supra note 62; Yakowitz, Drug Labeling and Promotion (Comments), 2o
Foon DRuG Costs. LJ. 97 (1965).
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New regulations 9 issued by the FDA on May 17, 1967, to which industry has
entered strong opposition, spell out that the FDA sees a third kind of fair balance
required for prescription drug advertising beyond that (i) within the brief summary
portion of the ad and (2) between the brief summary portion and the promotional
copy-namely, (3) within the promotional copy itself. Thus the new regulations,
as originally worded, order as follows:
Scope of information to be included in brief summary. (i) The advertisement as a
whole and each representation and suggestion in the advertisement shall be con-
sistent with the requirement that it present a true statement of information in
brief summary relating to side effects, contraindications, and effectiveness whether
or not it relies on a distinct part of the advertisement to present information relating
to side effects and contraindications.
This means that the ad must display the drug's limitations "in immediate conjunc-
tion with and as prominently as any claim for effectiveness," and that specific side
effects must appear in "immediate conjunction with" each claim for safety whether
or not such limitations and side effects are listed in a separate portion of the adver-
tisement. For ads of over three pages, the side-effect information must appear as a
"Brief Discussion Summary" which is "comparable in depth and detail" to that in
full-disclosure labeling, even if effectiveness claims are summarized, in addition to
appearing in the text next to any safety claims. In final form, the language of the
regulations will be modified to assure the industry that each sentence of an ad need
not present a complete report on the drug, although the ad as a whole must comply
with the FDA's requirements.
Although the FDA has disclaimed any intention of regulating advertising tech-
niques per se,90 the new rules cover comparative claims, traditionally disregarded
by the law as mere "puffing" which all but the most gullible consumers ignore. The
rules forbid any claim or suggestion-either directly or through cited references-
that a drug is better, safer, or more effective than its competitors, unless the claim
has been approved by the FDA for labeling or has been demonstrated by "sub-
stantial evidence." Moreover, any assertion of superiority must be balanced by dis-
closure of those disadvantages shared with the "inferior" drugs plus those draw-
backs unique to the "better" drug.
The agency's concern in this area may have stemmed from advertising for two
oral contraceptives. The FDA charged9 that Mead Johnson's description of Oracon
(ethinyl estradiol, dimethisterone) as safer than and superior to other birth control
pills was deceptive because there is no substantial evidence that one oral contraceptive
"' The regulations referred to in this and succeeding paragraphs may be found at 32 Fed. Reg.
7533-37 (May 23, 1967).
" Goodrich, Responsibilities and Problems of Government, in DRUGS IN OuR SocinTY 141, 146 (P.
Talalay ed. x964).
"IAddress by FDA General Counsel William W. Goodrich, N.Y.C. Pharmaceutical Advertising
Club Seminar, Oct. 2o, 1966, reported in 28 F.D.C. REI'oRTs No. 43, at S-io, S-Ix (Oct. 24, x966).
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outperforms the others, and that Eli Lilly wrongly claimed that women using its
C-Quens (mestranol, chlormadione acetate) will gain less weight than those using
nonsequential pills. The agency then required that labeling for all oral contraceptive
brands display exactly the same prescribing warnings, thereby effecting some
equalization of sales appeal. 2 Because six million American women are using these
pills, and because their safety has not yet been conclusively shown, such stringent
actions may be justified.
Exaggerated claims of superiority may achieve credibility when backed by an
impressive-looking block of citations. Many of the thirty-four specific practices
condemned in the new regulations pertain to the use of quotations and references
in ads. A kind of "fair balance" is required here also; thus an ad is misleading if
it
-ignores recent literature references for more favorable obsolete data;
-ignores published articles detailing side effects for literature reporting none;
-implies that a study reflects greater experience with the drug than it does in fact;
-fails to reveal that favorable studies conflict with other reliable studies; or
-improperly suggests that animal studies have clinical significance.
Even when accurately reported, studies cited in ads must have independent validity.
Drug firms may not cite a study "that lacks significance because it was uncontrolled
or for other reasons;" they must disclose the extent to which results claimed in
studies "may be due to placebo effect or concomitant therapy."
An alleged violation of the 1963 fair-balance rules, involving some of the factors
oudined above, led to the first seizure action under the advertising provisions of the
1962 amendments. On February 28, 1966, U.S. marshals seized sixty-eight bottles
containing ioo capsules each of Peritrate SA (pentaerythritol tetranitrate), sold by
the Warner-Chilcott Laboratories Division of the Warner-Lambert Pharmaceutical
Co., 3 which did not contest the action. Peritrate has been widely used since 1952 to
relieve the vise-like chest pain of angina pectoris, a coronary artery disease. Taken
by millions of patients, the drug enlarges blood vessels narrowed by fatty deposits
building up on their walls. But five-page journal ads04 suggested a new use for
Peritrate-prolonging the life of heart patients by reducing the chance of subsequent
attacks. Cited as support for this conclusion was one "long-range study of survival
in ioo patients," in "well-matched treatment groups." Charts printed against a
dramatic background of a sunset-lit ocean indicate that two years after myocardial
infarction, 771 per cent of the patients on Peritrate were still alive, in comparison
with 44.7 per cent of those given a placebo, demonstrating "a significant trend toward
02 Washington Post, Nov. 14, i966, at 3, col. '.
"
3 The discussion of Peritrate seizure is based on Wall Street Journal, March i, x966, at i, col. 1;
N.Y. Times, March 1, x966, at 22, col. a; MnicAL LErrR, Jan. 28, 1966; Washington Post, March 4,
1966, at 3, col. I.
"
4 E.g., J.A.M.A., Dec. 6, 1965, at 75-79.
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increased survival with Peritrate." On the last page of the ad a hand stretches
toward the sun; superimposed on the full-color picture is the question: "Is Peritrate
life-sustaining?"
The author of the cited study and the FDA answer that it is not. Dr. Alexander
Oscharoff, chief of cardiology at Queens Hospital Center and Union Health Center in
New York City, stated that he had never claimed "that Peritrate is the life-saving,
dramatic drug that the advertising makes it." Dr. Oscharoff said that the ads were
"distasteful," that he had "nothing to do" with them, and that after seeing them
he had "objected" to the manufacturer. The FDA similarly charged that the Peri-
trate ads "falsely represented" Dr. Oscharoff's investigation. In addition, the
Medical Letter has questioned the experiment itself, contesting the advertisement's
claim that the two groups of patients were "well-matched.""5 In fact, patients in the
placebo group were older and more severely ill from the start than those on Peritrate,
and therefore had dimmer chances of survival. The Letter concluded that "it seems
unlikely that the FDA would accept a single.., study by a single investigator" as
meaningful evidence for "one of the most intensive drug advertising campaigns of
recent years ... [which] promotes a drug as a lifesaving agent in a serious disease."
The advertisement contains three references in addition to Dr. Oscharoff's study,
which was published in a medical journal. Two were from inaccessible sources-
a paper presented by Dr. Oscharoff at the 1964 annual meeting in Detroit, Michigan,
of the Michigan Academy of General Practice, and "data on file" in the medical
department of the manufacturer. The other reference supposedly supports a claim
that Peritrate "stimulates development of collateral circulation." As the FDA
charged, the ad does not disclose that this study was made on piglets "in a manner
which in no way approximates the human disease situation." A second study by Dr.
Oscharoff was not cited; this revealed that the number of deaths among Peritrate
patients in the post-attack period was exactly the same as that among patients given
a placebo." A spokesman for JAMA, however, said that the Peritrate ads "met our
standards," which the Journal's advertising evaluation director has described as
limiting "claims for useful products to those which can be documented by scientific
fact."
In contrast, a recent three-page ad17 for Peritrate SA (billed as a "vignette of angina
pectoris") claims merely that the drug has "been reported in clinical usage to reduce
in number and severity the incidence of angina pectoris attacks," warning in the
next paragraph of the promotional text that "the published literature contains both
favorable and unfavorable clinical reports." The brief summary portion of the ad,
which occupies two-thirds of a page, discusses the tests on pigs and adds that "these
animal experiments cannot be translated to human behavior." However, the only
91 MEDIcAL LErra, Jan. 28, 1966.
" Washington Post, March 4, x966, at 3, col. X.
97J.A.M.A., July 31, 1967, at 6o-62.
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reference to this and other warning information on the two pages containing the
promotional copy (but largely consisting of irrelevancies) is the direction in small
print at the bottom of the second page, "See next page for full prescribing in-
formation."
In a speech to the New York City Pharamaceutical Advertising Club on Octo-
ber 20, I966,"l FDA general counsel William W. Goodrich criticized advertising
for the eight new drugs introduced in 1965 which within a year ranked among the
20o most frequently prescribed drugs. Among the advertisements termed false or
deceptive were the following:
Aventyl HC1 (nortriptyline hydrochloride), Eli Lilly-Promotion uses "a
new catch phrase to cover a host of 'target' symptoms, so that the drug is indi-
cated and prescribed for the ordinary frustrations of daily living to reach a much
larger patient population than the scientific data will support."
Indocin (indomethacin), Merck, Sharp & Dohme-Ad claims greater long-
term safety despite recent disclosure of new side effects; cites reference to support
effectiveness claim without disclosing that the same study found "striking failures
as well."
Lincocin (lincomycin hydrochloride monohydrate), Upjohn-Ad for antibiotic
"obscures the most important information that the MD needs in using this drug-
that hematologic toxicity can occur, and that the frequency of severe diarrhea is a
unique feature of Lincocin therapy."
Tegopen (sodium cloxacillin monohydrate), Bristol--"The artwork, layout,
and design of the ad" were meant "to impress the reader with the frequency
with which Tegopen can be used, and not to carry the real message which the
approval of the drug intended."
For the most part, the new regulations collect and codify advertising standards
previously communicated to industry through letters, articles, and speeches by agency
officials. By enumerating thirty or so specific practices as improper, the FDA hopes
to overcome the genuine difficulties involved in translating the few words of the
x962 statute and the generalities of the 1963 regulations into decisions made on par-
ticular ads by the agency and by manufacturers (some of whom may not have ade-
quate legal staffs). The industry withdrew its demands for a public hearing on the
1963 rules after then FDA Commissioner George P. Larrick sent two letters to
industry counsel commenting on specific ads, although industry stated that it did
not thereby concede that the FDA had broad regulatory powers over drug ad con-
tent.0 Following Dr. Goddard's appointment, agency officials have given a series
of some ten speeches to industry and its advertising agencies calling attention to
" Address by FDA General Counsel Goodrich, supra note 91, at S-so to S-I2.
"O Record at 131, 135, 137, In the Matter of Drugs: Prescription Drug Advertisements (Docket No.
FDC-D-78), Prehearing Conference (Sept. 26, 1963).
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faults in drug ads and urging greater self-regulation. The new regulations should
give more precise content to terms such as "fair balance."
Publicity attending the regulatory techniques used against defective ads has also
disseminated the FDA's interpretation of the law. More recently, the agency
has favored "dear doctor" letters from manufacturers to doctors to correct mis-
leading ads. These warning letters fine the alleged offender the amount of their cost
(about $4oooo), force a confession from him, and communicate the confession
directly to those persons whom the ad may have misled. Also, the advertiser has in
effect agreed to change all future promotion to match the correction. In contrast,
either an injunction against the ad or seizure of the drug would come too late. A
seizure action is effective from the FDA's point of view only if widely publicized.
But the industry complains that unfavorable publicity flowing from seizures may
result in sharp drops in sales because some doctors do not distinguish between defects
in advertising and total lack of efficacy and safety of the drug itself. Of course, some
danger exists that through the threat of seizure, injunction, criminal prosecution, and
consequent publicity, the FDA may be able to force its views on industry on points
that are reasonably debatable.
While it is true that FDA enforcement of its rules plus voluntary compliance by
industry have effected great changes in the format and content of drug ads, this
writer's survey of ads in recent journal issues indicates a wide divergence in under-
standing of the thrust of FDA policy. The separate, brief-summary portions of
prescription drug ads do not always conform to a standard of "readability." The type
size may be very small; 10 headings such as "side effects" may not clearly stand out
from the text;.0 ' all the information may be lumped into one paragraph and not
separated by white space;' indications already presented in the ad body may be
unnecessarily repeated; and warning data may be placed on the last page of a multi-
page spread where it can be overlooked. At the same time, many ads, especially one
and two-page spreads, present the summary of limitations in readable type close to
promotional claims' One ad varied this approach by stating in the promotional
text, in the same type face and size: "Side effects, occurring in 9% of patients, seldom
interfered with therapy. (For a description of side effects reported, see last page of
this advertisement.) "104 As the extreme case, an ad for Indocin (indomethacin)
presented four X-ray pictures, one sentence on uses, and twenty-five sentences of
warnings' 0 5
In a number of journal ads, promotional claims in large type, colorful drawings
.. E.g., Advertisement for Tepanil Ten-tab (diethylpropion hydrochloride), J.A.M.A., July 31, 1967,
at 12.
'20 E.g., Advertisement for Dilantin (diphenylhydantoin), J.A.M.A., July 24, 1967, at 64-65.
"'E.g., Advertisement for Miltrate (meprobamate, pentaerythritol tetranitrate), J.A.M.A., July 24,
1967, at 24-25.
'E.g., Advertisement for Kenalog (triamcinolone acetonide), J.A.M.A., Aug. 21, 1967, at 46-47.
' Advertisement for Vontrol (diphenidol), NEw ENG. J. MaD., July 6, x967, at viii-x.
"0" Advertisement for Indocin (indomethacin), J.A.M.A., July 31, 5967, at 7.
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and cartoons, and dramatic scenes portraying patients may overwhelm the cautionary
information. A two-page ad for Hygroton (chlorthalidone), an oral diuretic, was
composed of three horizontal strips running across facing pages. At the top was the
promotional text ("to get rid of the fussiness, get rid of the puffiness"); underneath,
and dominating the ad, a six-and-one-half-inch high picture of a woman's piercing
eyes and nose; under the picture, the small print of the warnings (one-half inch
high) was barely noticeable' 6
Although the FDA states that its regulations require an adequate explanation of
the limits of effectiveness, considerably different treatment is given to information sup-
porting effectiveness and information restricting a drug's usefulness-the former
appears in large type in the body of the ad, often with a citation, while the latter
is conveyed to the doctor through a summary statement without reference as a side
effect or contraindication, sometimes in an obscure part of the ad. Perhaps after
the issuance of the 1963 rules there arose some legitimate confusion over the require-
ment that warning information must become "part of the central message of the
advertisement." In two recent ads, statements that under certain conditions the
drug must be used only as adjunctive therapy appeared in the promotional text of
one ad107 but in the brief summary "indications" portion of the other'
According to a study cited at the Kefauver hearings,"0 9 doctors want less exag-
gerated and more informative ads, aimed at a higher level, accompanied by complete,
clear research statistics, without cartoons or sensationalism. Many drug companies
seem to have a low regard for the intellect of the average doctor. Consider, for
example, a twelve-page ad placed in JAMA"° in December 1965 by Warner-Chilcott
(which manufactures Peritrate SA) for Tedral and Brondecon. The ad begins:
"Like the Riders of the Apocalypse, to whom power was given to kill, there are
abroad in the land Four Horsemen of the Alveoli." The first three of the pathologic
"Horsemen" are identified as asthma, chronic bronchitis, and emphysema; the fourth,
"the pale rider of therapeutic despair and diagnostic discouragement," is portrayed
in a one-page color drawing as a naked man slumped wearily on a horse amidst dark
clouds. In large type, the ad asks "What can be done?" and ominously warns doctors
of impending influenza epidemics and air pollution--"There is cause for alarm."
"Much can be done," of course, by prescribing Tedral, "the air that comes in tablets."
Advertisements for tranquilizers and sedatives are particularly offensive, and have
more than likely contributed to the "astonishing expansion" in the use of such drugs
100 J.A.M.A., July 24, 1967, at 20-21.
107 Advertisement for Depo-Medrol (methylprednisolone acetate), J.A.M.A., July 24, 1967, at 32-33.
The ad text reads in part: 'In such chronic diseases as arthritis, Medrol should be regarded as adjunctive
therapy and not as replacement for standard measures."
"'Advertisement for Miltown (meprobamate), J.A.M.A., Aug. 21, 1967, at 25 8-i9. The ad's brief
summary portion reads in part: 'Indications: Effective in relief of anxiety and tension states; adjunctively
when anxiety may be causative or disturbing factor."
"' S. REP'. No. 448, at 163-64.
110 J.A.M.A., Dec. 6, 1965, at 11-22.
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and their "phenomenal abuse" by doctors within the past several yearsP Vividly
illustrated, these ads suggest that tranquilizers supply the answer to almost all social
problems-for the elderly woman "in senile agitation" clutching her dog, worried
because her pension check is late; for the husband yelling at his wife over a bill; for
the young woman crawling into bed with her teddy bear, nudged to sleep by a drug;
for the man who has lost his wife, job, or self-esteem; and for the unhappy person
experiencing "the fluctuating symptoms of Behavioral Drift." ("I keep pacing back
and forth. I think I'm going to pieces.") An ad promotes Miltown (meprobamate)
as helping to "control the underlying problem-anxiety- . . . when reassurance is
not enough,"" 2 an open-ended claim that sweeps broadly to catch a large proportion
of today's urban population who need more than reassurance, although not neces-
sarily Miltown. It is not surprising, therefore, that tranquilizers are being used less
as a medication than as agents for producing sleep, a sense of happiness, and relaxa-
tion."' Although the FDA could not order that advertisements be more dignified,
enforcement of the fair balance regulations plus general pressure toward scientific




The Kefauver Drug Amendments of 1962, and regulations issued by the Food and
Drug Administration to implement them, have produced significant and desirable
changes in prescription drug promotion. At the minimum, drug maufacturers
have complied with rules that are relatively unambiguous-that is, where non-
compliance would be conspicuous. Thus drug ads today at least list the side effects
associated with the promoted drug. And although it may be impossible to estimate
to what extent lack of full disclosure or unsubstantiated claims made in pre-1962 drug
literature caused misuse of drugs with consequent adverse effects, the new law
provides some safeguards against such occurrences." 4
Promotion for prescription drugs differs significantly from that for ordinary
consumer goods. Ads for consumer goods may stimulate aggregate demand for an
industry's product in addition to shifting demand among fungible brands of goods
(such as perfumes) which are quasi-useful and which lack any real potential for good
or harm. But no color photograph of a sunset '5 will ever create greater demand
for medication to treat one class of diseases (such as epilepsy). In fact, it is the
constant need for genuine medical progress, for the discovery and immediate use of
drugs with proven greater effectiveness and safety, that justifies regulatory control.
" N.Y. Times, March x3, 1966, at 32, col. 3 (city ed.).
112 J.A.M.A., Aug. 23, z967, at 218-ig.
11' N.Y. Times, March 13, 1966, at 32, col. 3 (city ed.).
,Pisani, supra note 68, at 75.
"'8Advertisement for Dilantin, supra note ioi.
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When such drugs are marketed, the "art of persuasion" and exaggerated claims-
or the failure to stress the unique limitation of a new drug among others used to
treat the same illness-must not lull doctors looking to ads for information into easy
acceptance either of inferior drugs or of equally effective drugs which may be in-
appropriate for a particular patient.
While physicians may be no more "immune to the contemporary scene" than other
persons, it does not follow that one cannot, "in a world dominated by singing com-
mercials and neon lights ... expect to attract attention to any message if you clothe
it in dull, eighteenth-century garb.""' 6 Doctors are not the ultimate consumers of
drugs; they are agents entrusted to exercise dispassionate scientific judgment on
scientific questions." 7 Communications phrased more like letters than billboards, with
relevant illustrations, are just as likely to catch the attention of a doctor treating a
patient for a painful, crippling disease as are more flamboyant, enthusiastic, and
colorful reviews. And if it is true that misleading advertising destroys doctors'
confidence in the pharmaceutical industry," 8 manufacturers should not hesitate
to rely on facts to sell drugs, "facts presented in a professional way for professional
men to read with care and respect."" 9
Dr. James L. Goddard, FDA Commissioner, has asked physicians to assist the
agency to review drug effectiveness and eliminate abuses in clinical testing of new
drugs. The medical profession could also take a more responsible stand in helping the
FDA monitor drug advertising by reporting adverse reactions not adequately
revealed in the brief summary; by expressing to detailers and manufacturers their
distaste for overpromotion; and by using publications such as the Medical Letter to
obtain more balanced pictures of drugs. Medical schools should take the initiative
in teaching doctors how to evaluate promotional literature and how to supplement
it with drug data from other sources.
Future relations between the FDA and industry will continue to include minor
skirmishing, with industry contesting some FDA regulatory actions against drug
promotion but acquiescing in others. The industry may contest the new advertising
regulations in court, having forced the FDA to retreat on the every-time requirement.
Recently drug companies have voluntarily submitted many ads for new drugs,
which the FDA watches carefully, for advance clearance by the agency. (The statute
bars the FDA from requiring advance approval except in "extraordinary circum-
stances."' 20) The industry has complained that the agency has been arbitrary in its
choice of ads to criticize and its choice of regulatory techniques to employ in indi-
vidual cases.
11 0Jurow, supra note 4, at 62, 63.
111 The fact that doctors act as purchasing agents for their patients minimizes the influences of prices
on the volume of prescription drug sales. Steele, supra note 14, at 132.
11I S. RaP. No. 448, at 155.
" Address by FDA Commissioner Goddard, supra note 5.
120 21 U.S.C. § 352(n) (1964).
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Ironically, just as the conflict over drug advertising intensifies, the importance of
medical journal advertising may be on the decline for a variety of reasons, which the
following paragraphs suggest.
First, companies may direct their promotional efforts more at hospitals and
government agencies and less at individual doctors reached through journals. Here
the detailers, over whose oral statements the FDA exercises little control, may play
a larger role. But large institutions cannot be misled or overawed as easily as can
the single practitioner; in addition, hospitals have programs for monitoring drug
reactions and effectiveness. In reviewing new drug labeling, the FDA has recently
been carefully examining the material prepared for the detailer to leave with doctors
during sales talks. And as more doctors become associated with hospitals or medical
centers, more will learn of the effectiveness and limitations of new drugs through
hospital and clinic committees.
Second, government agencies buying drugs under Medicare, Medicaid, and other
programs may limit buying to little-advertised generic name drugs. The sheer volume
of advertising for trade name drugs may obscure the existence of these generic drugs
from the general practitioner.' 2 '
Third, each year the number of new drugs, the most heavily advertised, decreases.
Thus, while forty-five new chemical entities were introduced in i96o, only thirteen
were introduced in 1966. Reasons for this decline may include the FDA's tightening
of rules on advertising content, which has diminished the manufacturers' ability to
differentiate their trade-name products. But more stringent FDA policies with regard
to testing and approving new drugs may have played a greater role in the reduction
in the flow of new drug products. 122
Fourth, techniques such as films and company-sponsored seminars may be stressed
to a greater extent. Today detailers may show films on drug use at medical con-
ventions and hospital meetings. Promotional films for one drug, or for a class of
drugs one of which is marketed by a sponsoring company, when used in a promo-
tional setting, are classified as labeling. In a concession to industry, the proposed
regulations require only that such films spell out the drug's "major" side effects,
provided they mention that full-disclosure information will be distributed to the
audience.
Fifth, publication of a government-approved manual on drugs, reproducing full-
disclosure labeling and updated with frequent supplements, may eventually replace
advertisements as a major source of drug information for doctors. As yet, however,
the industry has not agreed to subsidize such a publication, which would list drugs
by generic name.
121 Steele, supra note 14, at 147. According to William S. Comanor, assistant professor of economics
at Harvard University, the volume of advertising for a particular drug may in some cases be more
important than the ad content in inducing prescriptions from doctors who are uncertain about the relative
merits of competing products. Washington Post, Jan. 26, 1968, at 6, col. i (capital ed.).
" N.Y. TI'mes, Jude 4, 1967, § 3, at 1, col. 2.
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During the next several years industry and government, either in a spirit of
cooperation or in a mood of mutual and militant hostility, will determine the extent
of legal control over the advertising of prescription drugs. The final result will be
of great significance, for "except only those great decisions that lead to peace or war,
it is difficult to think of any that affect so many lives for so long to come or affect them
in such important ways."'
2 Address by Alanson WV. Willcox, General Counsel, Department of Health, Education, and Welfare,
Charles Wesley Dunn Lecture at Harvard Law School, March 15, 1963.
